Yahoo
    Tokyo - Delayed Quote JPY

    Astellas Pharma Inc. (4503.T)

    2,571.00 +58.00 (+2.31%)
    At close: October 30 at 3:30:00 PM GMT+9
    Loading Chart for 4503.T
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal

    Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal
    Pharmaceutical Technology 4d ago
    Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

    Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology
    PR Newswire 4d ago
    AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million

    AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
    Business Wire 11d ago
    Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

    Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
    PR Newswire 25d ago
    Astellas Pharma Inc's Dividend Analysis

    Astellas Pharma Inc's Dividend Analysis
    GuruFocus.com 1mo ago
    Astellas Pharma (TSE:4503) Stock Could Be 39% Below Fair Value On Cash Flow

    Astellas Pharma (TSE:4503) Stock Could Be 39% Below Fair Value On Cash Flow
    Simply Wall St. 1mo ago
    Astellas lists 431K sf Northbrook HQ in possible sale-leaseback play

    Astellas lists 431K sf Northbrook HQ in possible sale-leaseback play
    The Real Deal 1mo ago
    Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

    Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
    PR Newswire 1mo ago
    Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

    Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
    Benzinga 1mo ago
    Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines

    Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines
    PR Newswire 1mo ago
    Astellas Pharma (TSE:4503) Doses First Patient In Phase 3 Gastric Cancer Trial

    Astellas Pharma (TSE:4503) Doses First Patient In Phase 3 Gastric Cancer Trial
    Simply Wall St. 2mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: